01Impact factor
Impact factor of Endocrine Metabolic & Immune Disorders - Drug Targets (2026)
The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Endocrine Metabolic & Immune Disorders - Drug Targets published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, calculated by ScholarsColab. The journal is listed in JCR 2024, so it also has an official Journal Impact Factor published by Clarivate, which can differ because it counts citations from Web of Science journals only.
Rank in its subject categories
- Pharmacology & Pharmacyrank 267 of 371 journals
- Endocrinology & Metabolismrank 154 of 203 journals
- Immunologyrank 151 of 189 journals
Ranks here compare journals of the same Web of Science category in our data by 2-year citedness; they are not the official JCR rank.
Quartile of Endocrine Metabolic & Immune Disorders - Drug Targets
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Endocrine Metabolic & Immune Disorders - Drug Targets is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Citations and papers per year
Is your paper a fit for Endocrine Metabolic & Immune Disorders - Drug Targets?
Most desk rejections come from a scope mismatch. Compare your title and abstract with what this journal really publishes. Free, no sign-up, about 2 minutes.
Check my paper for this journalOr find journals that fit my paper
02Review time
Review time of Endocrine Metabolic & Immune Disorders - Drug Targets
Each paper took a different time. The green box holds the middle half of the papers and the dark line is the median; the whiskers reach the fastest 10% and the slowest 10%. Plan with the whole spread, not only the median.
Half of the research articles Endocrine Metabolic & Immune Disorders - Drug Targets published between Feb 2026 and Sep 2026 were accepted within 96 days of submission, and the middle half took between 78 and 118 days. This time includes peer review and any revision rounds. Papers that were rejected are not counted, because only published papers carry these dates.
In Pharmacology & Pharmacy, Endocrine Metabolic & Immune Disorders - Drug Targets ranks 57 of 157 journals by review time (1 = fastest). See the fastest-review journals in Pharmacology & Pharmacy →
Need a faster review? Endocrine Metabolic & Immune Disorders - Drug Targets takes a median of 96 days; the fastest journals in Pharmacology & Pharmacy take 3.
APC waivers and discounts for Endocrine Metabolic & Immune Disorders - Drug Targets
Bentham Science: 50% discount for corresponding authors in countries on Bentham's low-income list.
03Retractions
Retractions and research integrity at Endocrine Metabolic & Immune Disorders - Drug Targets
Most common reasons (a retraction can have several):
Endocrine Metabolic & Immune Disorders - Drug Targets has 1 retracted paper on record, the latest in Mar 2010. A retraction count is not a verdict on a journal: large journals publish more and journals that investigate actively retract more. The trend and the reasons tell you more than the number.
04Funders
Who funds research published in Endocrine Metabolic & Immune Disorders - Drug Targets
Funders named most often
A high share of funded papers usually means the journal is a common choice for grant-supported work in its field. If your funder pays article processing charges, or your country qualifies for a waiver, check what applies to your author team with the free APC waiver checker.
05Indexing
Indexing of Endocrine Metabolic & Immune Disorders - Drug Targets
- ISSN
- 1871-5303
- eISSN
- 2212-3873
- Publisher
- Bentham Science Publishers all its journals →
- Country
- U Arab Emirates
- Language
- English
- Scopus source type
- Journal
- Web of Science categories
- Endocrinology & Metabolism, Immunology, Pharmacology & Pharmacy
From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor on this page is calculated by ScholarsColab (see how the impact factor works).
Each link opens the official record for this journal, searched by its ISSN where we have one.
06How to submit
How to submit to Endocrine Metabolic & Immune Disorders - Drug Targets
- Read the guide for authors. It sets the article types, word limit, reference style and file format that Endocrine Metabolic & Immune Disorders - Drug Targets accepts. You find it on the journal's website at Bentham Science Publishers, usually under "For authors".
- Format to the journal's style. Check whether it wants a Word file, a LaTeX file or a PDF for the first submission, and follow its reference style; many journals accept any clear format at first and ask for their style only after acceptance. If the language or structure needs work first, manuscript editing by a PhD editor in your field is priced by word count (see the editing cost guide).
- Check the fit. Read the aims and scope and a few recent issues; papers outside the scope are the most common reason for a desk rejection. The Journal Finder shows journals that published the closest work.
- Check the fee. Endocrine Metabolic & Immune Disorders - Drug Targets is not a fully open access journal, so authors usually pay nothing unless they choose open access for their article or the journal charges page or colour fees. The guide for authors states the current charges.
- Check your manuscript before you submit. The free Submission Readiness Check asks the seven questions our reviewers ask in every audit and takes about 2 minutes.
07Reviewer comments
Reviewer comments and rejection reasons for Endocrine Metabolic & Immune Disorders - Drug Targets
No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.
Share reviewer comments for this journal →Across the reviewer comments researchers have shared with us, the points raised most often are figures, tables and equations (21%), literature and references (12%) and novelty and contribution (10%). Before you submit to Endocrine Metabolic & Immune Disorders - Drug Targets, a Manuscript Audit by a PhD reviewer in your area checks your paper against exactly these points.
Audit my paper before I submit →Worried about the English? Manuscript editing by editors in your subject: see the price →
Not sure yet? Check if your paper is ready for this journal: free, no AI, under 5 seconds08Same subject
Pharmacology & Pharmacy journals with a similar impact factor*
The journals next to Endocrine Metabolic & Immune Disorders - Drug Targets when the 354 journals of Pharmacology & Pharmacy in our data are ranked by impact factor*:
| Rank | Journal | Impact factor* | Indexing | Open access |
|---|---|---|---|---|
| 263 | Journal of Pharmacy And Bioallied Sciences | 1.54 | ESCI | Fully open access |
| 264 | Clinical Pharmacology in Drug Development | 1.53 | SCIE | Subscription |
| 265 | Current Drug Safety | 1.51 | ESCI | Subscription |
| 266 | Revista Española de Quimioterapia | 1.50 | SCIE | Fully open access |
| 268 | American Journal of Health-System Pharmacy | 1.48 | SCIE | Subscription |
| 269 | Iranian journal of pharmaceutical research | 1.42 | SCIE | Subscription |
| 270 | Indian Journal of Pharmaceutical Education and Research | 1.41 | SCIE | Subscription |
| 271 | Clinical Neuropharmacology | 1.41 | SCIE | Subscription |
*Impact factor calculated by ScholarsColab (2-year citedness), not the official Clarivate value.
Is Endocrine Metabolic & Immune Disorders - Drug Targets right for your paper? Find the right journal
Paste your title, keywords or abstract. See the journals that published the closest papers, with indexing, impact factor, review time and APC.
No AI or language model is used. Your words are matched against the titles of 157,375 real published journal papers, by our mentors and by other researchers (shown without names); journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; the impact factor is calculated by ScholarsColab, not the official Clarivate value, and no quartile is shown until the official JCR or SJR quartile can be; review time is the median days from submission to acceptance (not every publisher publishes these dates). Always check a journal’s scope and current indexing before submitting.
09Questions
Frequently asked questions
How long is the review time of Endocrine Metabolic & Immune Disorders - Drug Targets?
Based on 185 research articles Endocrine Metabolic & Immune Disorders - Drug Targets published from Feb 2026 to Sep 2026, the median time from submission to acceptance was 96 days, and half of them were accepted between 78 and 118 days. After acceptance, papers appeared online after a median of 183 days. Data updated October 2026. Individual papers can take longer, especially with major revisions.
What is the impact factor of Endocrine Metabolic & Immune Disorders - Drug Targets?
Based on ScholarsColab citation data (October 2026), the 2-year impact factor of Endocrine Metabolic & Immune Disorders - Drug Targets is 1.50: papers it published in the two previous years were cited 1.50 times on average in a year. The journal is listed in JCR 2024, so Clarivate also publishes an official Journal Impact Factor, which can differ.
What is the h-index of Endocrine Metabolic & Immune Disorders - Drug Targets?
The h-index of Endocrine Metabolic & Immune Disorders - Drug Targets is 67 (October 2026): 67 of its papers have each been cited at least 67 times. Its i10-index is 728.
What is the quartile of Endocrine Metabolic & Immune Disorders - Drug Targets?
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Endocrine Metabolic & Immune Disorders - Drug Targets is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Is Endocrine Metabolic & Immune Disorders - Drug Targets indexed in Scopus?
Yes. Endocrine Metabolic & Immune Disorders - Drug Targets appears in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Endocrine Metabolic & Immune Disorders - Drug Targets an SCIE journal?
Yes. Endocrine Metabolic & Immune Disorders - Drug Targets is listed in the Science Citation Index Expanded (SCIE), according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Endocrine Metabolic & Immune Disorders - Drug Targets in Journal Citation Reports (JCR)?
Yes. Endocrine Metabolic & Immune Disorders - Drug Targets is listed in JCR 2024, so it has a Journal Impact Factor. For the current impact factor and quartile, check Journal Citation Reports.
Does Endocrine Metabolic & Immune Disorders - Drug Targets offer an APC waiver?
Endocrine Metabolic & Immune Disorders - Drug Targets follows the policy of Bentham Science: 50% discount for corresponding authors in countries on Bentham's low-income list. Only the corresponding author's affiliation counts. Co-authors from other countries do not change the waiver. Rules verified 27 October 2026; confirm on the publisher's page.
Has Endocrine Metabolic & Immune Disorders - Drug Targets retracted papers?
Yes. 1 retracted paper are on record for Endocrine Metabolic & Immune Disorders - Drug Targets, 0 of them in the last 10 years; the most common reasons are duplication of/in article. A retraction count alone is not a verdict on a journal; look at the trend and the reasons. Data updated October 2026.
Who funds research published in Endocrine Metabolic & Immune Disorders - Drug Targets?
1% of 200 recent research articles in Endocrine Metabolic & Immune Disorders - Drug Targets name a funder; the funders named most often are Science and Technology Program of Guizhou Province, Taizhou Social Development Science and Technology Plan Project, Excellent Young Talents Plan of Guizhou Medical University.
Popular journals
- The Lancet
- Nature
- Science
- PLoS ONE
- Scientific Reports
- Journal of the American Chemical Society
- Journal of Colloid and Interface Science
- Physical Chemistry Chemical Physics
- Science of the Total Environment
- Physical Review C
- Environmental Science and Pollution Research
- Materials Letters
- Astronomy and Astrophysics
- Nature Communications
- Materials Science and Engineering: A
- International Journal of Hydrogen Energy
- Journal of Cleaner Production
- Applied Surface Science
- Journal of Magnetism and Magnetic Materials
- Remote Sensing
Browse all journals: indexing, impact factor and reviewer comments →